A securities class action has been filed against West Pharmaceutical Services, Inc. (WST) on behalf of persons and entities that purchased or otherwise acquired West common stock between February 16, 2023 through February 12, 2025. This case has been filed in the USDC – EDPA.
On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts’ expectations. Management attributed the low guidance to currency headwinds, operating expenses and “glucose monitoring transition.” Analysts expressed shock and disappointment at the Company’s full year 2025 outlook.
Following this news, WST’s stock price fell by $123.17 per share, or approximately 38% to close at $199.11 per share.